| 32.12 2.52 (8.51%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.88 |
1-year : | 47.74 |
| Resists | First : | 35 |
Second : | 40.88 |
| Pivot price | 31.58  |
|||
| Supports | First : | 30.4 |
Second : | 27.55 |
| MAs | MA(5) : | 30.23 |
MA(20) : | 31.8 |
| MA(100) : | 32.93 |
MA(250) : | 22.76 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 37.9 |
D(3) : | 31.9 |
| RSI | RSI(14): 53.6 |
|||
| 52-week | High : | 44.88 | Low : | 9.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MBX ] has closed below upper band by 42.8%. Bollinger Bands are 14.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.35 - 32.47 | 32.47 - 32.62 |
| Low: | 28.75 - 28.87 | 28.87 - 29.01 |
| Close: | 31.87 - 32.09 | 32.09 - 32.33 |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Thu, 07 May 2026
Former Alnylam, Pfizer executive joins MBX as commercial chief - Stock Titan
Wed, 06 May 2026
FMR LLC discloses 2.94M shares in MBX Biosciences (MBX) under Schedule 13G - Stock Titan
Mon, 04 May 2026
MBX Biosciences (NASDAQ: MBX) director awarded RSUs and 74,249 stock options - Stock Titan
Fri, 01 May 2026
MBX (MBX) Rule 144: Bartram sold 21,484 shares; Fidelity lists 5,000 - Stock Titan
Tue, 28 Apr 2026
MBX SEC Filings - MBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 03 Apr 2026
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 105.3 (%) |
| Shares Short | 3,790 (K) |
| Shares Short P.Month | 2,980 (K) |
| EPS | -2.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.22 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.8 % |
| Return on Equity (ttm) | -27.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -80 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -13.5 |
| PEG Ratio | 0 |
| Price to Book value | 3.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -19.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|